Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 16;13(10):e18818.
doi: 10.7759/cureus.18818. eCollection 2021 Oct.

Current Therapeutic Use of Metformin During Pregnancy: Maternal Changes, Postnatal Effects and Safety

Huma Quadir  1   2
Affiliations
Review

Current Therapeutic Use of Metformin During Pregnancy: Maternal Changes, Postnatal Effects and Safety

Huma Quadir. Cureus. .

Abstract

Metformin is one of the most easily available medications for diabetes and has a relatively low cost. It is not only used in diabetes but is also effective in polycystic ovarian syndrome (PCOS) and obesity. Although insulin is the first choice when it comes to treating pregnant women with gestational diabetes mellitus (GDM), metformin has also been debated as a good choice after modification of diet. As metformin passes through the placenta, it is essential to know its consequence of leading to insulin resistance in the fetus as well as the impact on postnatal development. The use of metformin during GDM has raised many trials demonstrating that outcomes from the use of metformin are similar to those achieved with insulin. Follow-up studies were also conducted that assessed the impact on children exposed to metformin in utero. This review highlights the experimental evidence relating to the use of metformin during pregnancy for different conditions, and its impact on the growth and development of offspring.

Keywords: gdm; insulin; maternal obesity; metformin; oct; pcos; postnatal; postpartum; pregnancy; types 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Metformin-induced complex I inhibition.
OCT: Organic Cation Transporter; AMP: Adenosine Monophosphate; ATP: Adenosine Triphosphate; AMPK: AMP-activated protein kinase Original diagram
See this image and copyright information in PMC

References

    1. Population pharmacokinetics of metformin in late pregnancy. Charles B, Norris R, Xiao X, Hague W. Ther Drug Monit. 2006;28:67–72. - PubMed
    1. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J. Curr Pharm Des. 2017;23:2532–2550. - PubMed
    1. Expression, localization, and function of the carnitine transporter OCTN2 (SLC22A5) in human placenta. Grube M, Meyer Zu Schwabedissen H, Draber K, et al. Drug Metab Dispos. 2005;33:31–37. - PubMed
    1. Organic cation transporter 3 facilitates fetal exposure to metformin during pregnancy. Lee N, Hebert MF, Wagner DJ, Easterling TR, Liang CJ, Rice K, Wang J. Mol Pharmacol. 2018;94:1125–1131. - PMC - PubMed
    1. Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. Lee N, Hebert MF, Prasad B, Easterling TR, Kelly EJ, Unadkat JD, Wang J. Drug Metab Dispos. 2013;41:2225–2232. - PMC - PubMed

LinkOut - more resources